Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialGARON, Edward B; CIULEANU, Tudor-Eliade; CZYZEWICZ, Grzegorz et al.Lancet (British edition). 2014, Vol 384, Num 9944, pp 665-673, issn 0140-6736, 9 p.Article

Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain MetastasesSIOW MING LEE; LEWANSKI, Conrad R; COUNSELL, Nicholas et al.Journal of the National Cancer Institute. 2014, Vol 106, Num 7, issn 0027-8874, dju151.1-dju151.7Article